<DOC>
	<DOCNO>NCT00829933</DOCNO>
	<brief_summary>The primary objective study compare incidence hemorrhagic event patient treat non-valvular atrial fibrillation DU-176b dose level versus warfarin potassium ( warfarin ) . The secondary objective include between-group comparison regard incidence thromboembolic event , pharmacodynamic parameter , biomarkers efficacy evaluation , well incidence adverse event adverse reaction safety evaluation .</brief_summary>
	<brief_title>Late Phase 2 Study DU-176b Patients With Non-Valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients nonvalvular atrial fibrillation meet follow requirement consider admission study : Age≧20years Atrial fibrillation confirm least 2 electrocardiographic ( ECG ) trace take interval ≧1week year enrollment Presence ( least ) one follow risk factor embolism : Hypertension Diabetes mellitus Congestive heart failure Previous transient ischemic attack ( TIA ) cerebral infarction ( 30 day give informed consent ) Age≧75 year At time give informed consent . To confirm ECG chart , etc . Presence follow condition increase risk hemorrhage : History intracranial , intraocular ( exclude bleed beneath bulbar conjunctiva ) , intrathecal , retroperitoneal , nontraumatic intraarticular hemorrhage History gastrointestinal hemorrhage year give informed consent History peptic ulcer 90 day give informed consent Surgical treatment trauma require hospitalization 30 day give informed consent Hemoglobin level &lt; 10 g/dL platelet count &lt; 10 ×10000 /μL screen examination Active hemorrhage* present give informed consent enrollment Any invasive therapeutic diagnostic procedure ( e.g. , surgery , tissue , biopsy , tooth extraction ) schedule period time informed consent completion trial treatment . Any congenital hemorrhagic disease History cerebral infarction TIA within 30 day give informed consent Current treatment anticoagulant ( warfarin ) Concurrent rheumatic valvular disease History valvular surgery Concurrent infectious endocarditis Concurrent cardiac myxoma Confirmed leave ventricular leave atrial thrombosis Any congenital condition tendency toward thrombosis Electrical pharmacological defibrillation schedule trial treatment Uncontrolled hypertension ( persistently high systolic ［ &gt; 160mmHg］or diastolic [ &gt; 100mmHg ] pressure ) Uncontrolled diabetes mellitus Renal hepatic dysfunction ( define ) , confirm screening examination Serum creatinine &gt; 1.5mg/dL AST ( GOT ) ALT ( GPT ) ≧twice upper limit reference range Total bilirubin ≧twice upper limit reference range Current antiplatelet therapy concomitant illness may aggravate discontinuation therapy . Any concurrent severe cardiac disease Known allergy warfarin condition contraindicate use Inability discontinue current treatment vitamin K Confirmed potential pregnancy , wish become pregnant study period , current breast feed Previous treatment DU176b Participation trial drug 6 month give informed consent Any condition disqualifies patient study opinion investigator/subinvestigator *This include ecchymosis identify least one hematoma size ≧5 cm longer diameter , macroscopic hematuria , microscopic hematuria define ≧2+test 1+ test occult blood urine sediment contain ≧10 red cell per highpower field ( except 2+ occult blood test persist 1 year give informed consent ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Factor Xa inhibition</keyword>
</DOC>